First-line treatment with subcutaneous epcoritamab plus R-CHOP in patients with high-risk diffuse large b-cell lymphoma (DLBCL): Phase 1/2 data update
Authors
Falchi, L.Offner, F.
Belada, D.
Brody, J.
Linton, Kim M
Karimi, Y.
Cordoba, R.
Snauwaert, S.
Abbas, A.
Wang, L. W.
Wu, J.
Elliott, B.
Clausen, M. R.
Affiliation
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York,Issue Date
2022